Replies to post #36767 on OncoSec Medical Inc (ONCSQ)

[dr_lowenstein]

well now we seem to be making some progress as we are no longer talking about electroporating PD1 inhibitors, but instead taking about ep of DNA encoding for PD1 inhibitors. However, no compelling explanation of the reason for doing this has been offered. thanks

[goodJohnhunting]

My primary question is whether or not the immune response would play out this way when you electroporate checkpoint inhibitor DNA in the tumor cells and in these settings.

The transition from Cellular pathogenesis to normal apoptotic cell cycle starts by immune recognition of "self", from "non-self" in a tumor mircoenvironment.. The issue with oncogenesis is that once this is broken down, it's difficult to revert the transformation.. It's possible to remove (surgical) and kill (chemo) tumor cells, but transitioning them is difficult.. But, not impossible..

The ability to transition is multifaceted, and as I mentioned would require recognition of non-self, or in the least recognize the deception by which tumor cells avoid apoptosis. It's unlikely that one single therapeutic would be able to change the "decoy" and at the same time circumvent the "transition" abilities of oncogenic cellular chemistry to survive. In other-words recognize, and alter tumor DNA's limitless life cycle.

However, if the goal is to change tumor DNA for the purpose of altering it's offspring, then the only way would be intracellular (intratumorally), as opposed to extrocellular manipulation.

So, this is what EP DNA Presenting technology is trying to execute, IMO.. Present Plasmid DNA that alters mitotic tumor cell code, into cells that obey the "Hayflick Limit".. Then and only then would there be systemic abscopal effect, IMO..

All the best,
John